In the context of MASLD/MASH pathogenesis, the effects of an antidiabetic drug (pioglitazone) in alleviating liver fibrosis through modulation of TGF-β signaling have been explored (Kasahara et al., 2023). This evidence concerns the gene TGFB1 and Hepatic fibrosis.